Ipsen delivers encouraging sales growth in Q1, confirms full-year guidance

We are pleased to announce encouraging sales growth of 5.5% at CER (0.6% as reported) in the first quarter of 2021, driven by our Specialty Care portfolio, despite the ongoing impact of the pandemic.

 

We are also pleased to confirm our 2021 full-year guidance: total Group sales growth of more than 4% at CER and a Core Operating Margin greater than 30% of sales.

 

“We delivered a strong performance in the first quarter, despite the persistently difficult COVID-19 environment, driven by our unrelenting focus on patients. Our execution was in line with our plans and our financial guidance for the year,” said David Loew, CEO.

 

“We continue to support our ambitions of strengthening the pipeline and driving sustainable growth, based on our patient-focused strategy. I am very proud of the great execution by colleagues around the world, especially as many teams continue to experience challenging conditions during the pandemic,” he continued.

 

For more information, read the press release here: https://www.ipsen.com/press-releases/ipsen-delivers-encouraging-sales-growth-in-the-first-quarter-of-2021-despite-the-pandemic-and-confirms-its-full-year-guidance/

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021